Psychedelic-assisted therapy is emerging as a novel form of mental health treatment that has been shown to be highly effective in early clinical trials. This workshop will provide an overview of this new clinical area. First, a history of the use of psychedelics will be reviewed that includes an appreciation for their long-standing use by many indigenous cultures. Next, the two major waves of psychedelic research will be summarized, with emphasis on more recent and rigorous clinical trials. The basic model of psychedelic-assisted psychotherapy will be explained so that workshop participants will have a better sense of how this treatment works. The workshop will highlight the importance of preparation and integration, as well as how to use a harm reduction approach to provide therapeutic support to clients using psychedelics on their own now. Finally, the workshop will outline the ethical and legal risks for practicing psychedelic harm reduction and integration therapy given the legal status of psychedelics and that it is a new clinical area.
CONTINUING EDUCATION (CE) OBJECTIVES
Following this presentation, participants will be able to:
This presentation is intended for licensed mental health professionals and graduate student trainees. The instructional level of this presentation is beginner and no prior knowledge or experience with psychedelics is necessary.
About the presenter
Brian Pilecki, PhD: Dr. Brian Pilecki is a clinical psychologist at Portland Psychotherapy that specializes in the treatment of anxiety disorders, trauma and PTSD, and psychedelic-assisted therapy. He graduated from Fordham University and completed a post-doctoral fellowship at The Warren Alpert Medical School of Brown University. Brian practices from an orientation based in Acceptance and Commitment Therapy (ACT) and has extensive experience in the areas of mindfulness and meditation that he incorporates into therapy with clients. At Portland Psychotherapy, Brian is an active researcher and a study therapist on a clinical trial investigating the use of MDMA-assisted therapy for the treatment of social anxiety disorder and understanding processes of change in how this novel form of treatment might work. He has given numerous workshops on topics related to psychedelics and is a consultant and instructor for Fluence, an organization that provides professional training in psychedelic-assisted therapy and integration. Brian is co-chairperson for the Psychedelic Special Interest Group in the Association for Contextual Behavioral Science and co-hosts a podcast called Altered States of Context about the intersection of psychedelics and psychotherapy.
This presentation is intended for licensed mental health professionals and graduate student trainees. The instructional level of this presentation is beginner.
Copyright Philadelphia Behavior Therapy Association